People with allergic fungal rhinosinusitis taking Dupixent (dupilumab) saw significant improvement in congestion and sinus ...
Phase 3 LIBERTY-AIMS results showed dupilumab reduced nasal polyp size and sinus symptoms in adults and children with allergic fungal rhinosinusitis.
Dupixent (dupilumab) is now FDA-approved for adults and children aged 6 years and older with allergic fungal rhinosinusitis and prior sino-nasal surgery.
The FDA approved Dupixent as the first treatment for allergic fungal rhinosinusitis in adults and children over six years old ...
Your nose is runny and stuffy and your throat is sore. Could it be the start of a cold or a sinus infection? Or is it allergies? The symptoms of these conditions each overlap somewhat, but health ...
The FDA has approved dupilumab to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older.
The FDA granted approval to dupilumab for treating patients aged 6 years and up with allergic fungal rhinosinusitis and a history of sino-nasal surgery, marking the first treatment approved for this ...
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and ...
What if you'd been treated for years for a condition, only to find out that you'd long ago been misdiagnosed? That's what's happening to a sizable number of Americans who are taking allergy meds (to ...
The approval makes Dupixent the first FDA-approved therapy for allergic fungal rhinosinusitis, supported by Phase III data showing significant improvements in sinus opacification, nasal symptoms, and ...
Approval covers adults and children ≥6 years with prior sinonasal surgery, representing the first FDA-cleared pharmacologic option specifically for AFRS and dupilumab’s ninth U.S. indication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results